RTW Biotech Opportunities Ltd USD · LSE:RTW
RTW Biotech Opportunities Ltd USD — RTW Biotech Opportunities — Fact Sheet (September 2025)
5 slides from RTW Biotech Opportunities Ltd USD's fact sheet, Sep 30, 2025
Slide 1: Monthly Factsheet + Quarterly Letter, 30 September 2025
auwe Monthly Factsheet + Quarterly Letter 30 September 2025 rtWe= Opportunities Identifying and developing next- generation therapies that aim to KEY CURRENT STATISTICS significantly improve the lives of $695.5M $212 patients Ordinary NAV NAV per ordinary share RTW Biotech Opportunities Ltd (the “Co
Slide 2: Top portfolio positions, exposures and attribution
Description % Public/ Clinical Proximate p NAV Private Stage’ Catalysts! Developing medicines for people living with rare neurologic and metabolic Public Translarna PTC conditions disorders. 10.6% “TCT” Commercial ED, decision RTW-incubated biotech company committed to bringing innovative therapies
Slide 3: Third Quarter 2025 Company, Performance and Sector Update
aus POW e220 THIRD QUARTER 2025 COMPANY UPDATE On 11 September, RTW Bio released its interim results to 30 June and held an investor webinar, presented by Rod Wong and Woody Stileman. The interim results, presentation, and webinar recording can all be found on RTW Bio’s website. Earlier in the year,
Slide 4: Portfolio Update - September
anes POW e220 THIRD QUARTER 2025 PORTFOLIO UPDATE - SEPTEMBER On 29 September, Genmab agreed to acquire Merus for $8 billion, a 41% premium to Merus' 26 September closing price. As of 31 August, Merus made up 1.18% of the Company’s NAV. On 24 September, uniQure announced positive topline results fro
Slide 5: Key RTW personnel, board and fund information
Key RTW personnel for RTW Biotech Opportunities Ltd: Roderick Wong, MD, Portfolio Manager; Naveen Yalamanchi, MD, Portfolio Manager; Peter Fong, PhD, RTW President; Stephanie Sirota, Chief Business Officer; Woody Stileman, Managing Director, Business Development; Oliver Kenyon, Senior Director, Busi
RTW Biotech Opportunities — Fact Sheet (September 2025) on 6ix